Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.85 |
| ▸ | NOS1 | P29475 | 9/20 | 0.51 |
| ▸ | AKR1B1 | P15121 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15144421 | 1.00 | HSD17B10 (0.85) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL13947293 | 1.00 | HSD17B10 (0.85) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL29776929 | 1.00 | HSD17B10 (0.85) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL29400382 | 1.00 | HSD17B10 (0.85) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL29776986 | 1.00 | HSD17B10 (0.85) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL258468 | 1.00 | HSD17B10 (0.85) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL30515237 | 0.89 | HSD17B10 (0.68) | HSD17B10AKR1B1 | |
| SCHEMBL25899101 | 0.85 | HSD17B10 (0.71) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL6363183 | 0.85 | HSD17B10 (0.71) | HSD17B10NOS1AKR1B1KDM4EMEN1 | |
| SCHEMBL13314521 | 0.84 | HSD17B10 (0.69) | HSD17B10NOS1AKR1B1KDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220298178-A1 | METHOD FOR PREPARING L-ERYTHROBIOPTERIN COMPOUND | SHANGHAI FOREFRONT PHARMA CO., LTD. (CN) | 2022-09-22 | — | — | US | disclosed |
| EP-4019523-A1 | METHOD FOR PREPARING L-ERYTHROBIOPTERIN COMPOUND | Shanghai Forefront Pharma Co., Ltd. (CN) | 2022-06-29 | — | — | EP | disclosed |
| WO-2021032088-A1 | METHOD FOR PREPARING L-ERYTHROBIOPTERIN COMPOUND | 上海众强药业有限公司 | 2021-02-25 | — | — | WO | disclosed |
| EP-2582711-B1 | PROCESS FOR THE PREPARATION OF PTERIDINE DERIVATIVES | DIPHARMA FRANCIS SRL (IT) | 2014-11-12 | — | — | EP | disclosed |
| US-8809553-B2 | Process for the preparation of pteridine derivatives | DIPHARMA FRANCIS S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| US-8809553-B2 | Process for the preparation of pteridine derivatives | DIPHARMA FRANCIS S.R.L. (IT) | 2014-08-19 | — | — | US | disclosed |
| US-20130090474-A1 | PROCESS FOR THE PREPARATION OF PTERIDINE DERIVATIVES | DIPHARMA FRANCIS S.R.L. (IT) | 2013-04-11 | — | — | US | disclosed |
| US-20130090474-A1 | PROCESS FOR THE PREPARATION OF PTERIDINE DERIVATIVES | DIPHARMA FRANCIS S.R.L. (IT) | 2013-04-11 | — | — | US | disclosed |
| US-8178670-B2 | Method of synthesizing tetrahydrobiopterin | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178670-B2 | Method of synthesizing tetrahydrobiopterin | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-05-15 | — | — | US | disclosed |
| US-20090076305-A1 | METHOD FOR PRODUCING HYDRAZONE DERIVATIVES | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090076305-A1 | METHOD FOR PRODUCING HYDRAZONE DERIVATIVES | SHIRATORI PHARMACEUTICAL CO., LTD. (JP) | 2009-03-19 | — | — | US | disclosed |
| US-20090030191-A1 | Process for Producing Carbon-Reduced Aldose Compounds | ASUBIO PHARMA CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| US-20090030191-A1 | Process for Producing Carbon-Reduced Aldose Compounds | ASUBIO PHARMA CO., LTD. (JP) | 2009-01-29 | — | — | US | disclosed |
| WO-2008109181-A2 | METALLOPROTEASE INHIBITORS CONTAINING A HETEROCYCLIC MOIETY | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2008-09-12 | — | — | WO | disclosed |
| US-7361759-B2 | large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants; reacting a triacetoxy-5-deoxy-L-arabinose phenylhydrazone with 6-hydroxy-2,4,5-triaminopyrimidine | SHIRATORI PHARMACEUTICAL CO., LTD (JP) | 2008-04-22 | — | — | US | disclosed |
| US-7361759-B2 | large industrial scale by using a reagent which is inexpensive and easy to handle, without requiring a use of any particular equipment or plants; reacting a triacetoxy-5-deoxy-L-arabinose phenylhydrazone with 6-hydroxy-2,4,5-triaminopyrimidine | SHIRATORI PHARMACEUTICAL CO., LTD (JP) | 2008-04-22 | — | — | US | disclosed |
| EP-1849793-A1 | PROCESS FOR PRODUCING CARBON-DIMINISHED ALDOSE COMPOUND | Asubio Pharma Co., Ltd. (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-20070244322-A1 | Process for Preparing Tetrahydrobiopterin and Analogs of Tetrahydrobiopterin | MERCK EPROVA AG (CH) | 2007-10-18 | — | — | US | disclosed |
| US-20070244322-A1 | Process for Preparing Tetrahydrobiopterin and Analogs of Tetrahydrobiopterin | MERCK EPROVA AG (CH) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130090474-A1 | PROCESS FOR THE PREPARATION OF PTERIDINE DERIVATIVES | G6PD, DPYD, FBP1 | HSD17B10 2072/4885NOS1 2027/4885AKR1B1 298/4885 |
| US-20090030191-A1 | Process for Producing Carbon-Reduced Aldose Compounds | ALDOA, DERA, UGT1A6 | HSD17B10 487/4885NOS1 3214/4885AKR1B1 23/4885 |
| US-20090076305-A1 | METHOD FOR PRODUCING HYDRAZONE DERIVATIVES | CYP3A5, DHPS, ALDH5A1 | HSD17B10 20/4885NOS1 798/4885AKR1B1 263/4885 |
| US-20070244322-A1 | Process for Preparing Tetrahydrobiopterin and Analogs of Tetrahydrobiopterin | SPR, DHPS, BLVRB | HSD17B10 1062/4885NOS1 1075/4885AKR1B1 956/4885 |
| US-20220298178-A1 | METHOD FOR PREPARING L-ERYTHROBIOPTERIN COMPOUND | SPR, RNPEP, DHPS | HSD17B10 541/4885NOS1 1621/4885AKR1B1 471/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.